# Thermo Fisher SCIENTIFIC

## SelectScreen™ Biochemical Kinase Profiling Service

## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 1 of 40

ASSAY THEORY _							3
Z'-LYTE ASSAY CO	DNDI	TIONS					4
Z'-LYTE ASSAY CO	NTR	ols					5
Z'-LYTE DATA ANA	LYS	ıs					6
KINASE-SPECIFIC	ASS	AY CONDITIONS - D	IREC	T FORMAT			8
ABL1	8	DYRK1B	14	KIT V559D V654A	20	PLK2	26
ABL1 E255K ABL1 F317I	8	DYRK3 DYRK4	14 14	KIT V560G KSR2	20 20	PLK3 PRKACA (PKA)	27
ABL1 F317L	8	EEF2K	14	LCK	21	PRKCA (PKC alpha)	27 27
ABL1 G250E	8	EGFR (ErbB1)	14	LTK (TYK1)	21	PRKCB1 (PKC beta I)	27
ABL1 T315I	8	EGFR (ErbB1) C797S	14	LYN A	21	PRKCB2 (PKC beta II)	27
ABL1 Y253F ABL2 (Arg)	8	EGFR (ErbB1) G719C EGFR (ErbB1) G719S	14 15	LYN B MAP3K19 (YSK4)	21 21	PRKCD (PKC delta) PRKCE (PKC epsilon)	27 27
ABL2 (Arg) ACVR1B (ALK4)	8	EGFR (ErbB1) G719S EGFR (ErbB1) L858R	15	MAP3K19 (YSK4) MAP3K9 (MLK1)	21	PRKCE (PKC epsilon) PRKCG (PKC gamma)	27
ADRBK1 (GRK2)	8	EGFR (ErbB1) L861Q	15	MAP4K2 (GCK)	21	PRKCH (PKC eta)	27
ADRBK2 (GRK3)	8	EGFR (ErbB1) T790M	15	MAP4K4 (HGK)	21	PRKCI (PKC iota)	27 27
AKT1 (PKB alpha)	9	EGFR (ErbB1) T790M C797S L858R	15	MAP4K5 (KHS1)	21	PRKCN (PKD3)	28
AKT2 (PKB beta) AKT3 (PKB gamma)	9	EGFR (ErbB1) T790M L858R EPHA1	15	MAPK1 (ERK2) MAPK11 (p38 beta)	21 21	PRKCQ (PKC theta) PRKCZ (PKC zeta)	28 28
ALK	9	EPHA2	15 15	MAPK11 (p36 beta) MAPK12 (p38 gamma)	21 22	PRKD1 (PKC zeta)	28
AMPK (A1/B2/G2)	9	EPHA4	15	MAPK13 (p38 delta)	22	PRKD2 (PKD2)	28
AMPK (A1/B2/G3)	9	EPHA5	15	MAPK14 (p38 alpha) Direct	22 22	PRKG1	28
AMPK (A2/B1/G2)	9	EPHA8	16	MAPK3 (ERK1)	22	PRKG2 (PKG2)	28
AMPK (A2/B1/G3) AMPK (A2/B2/G3)	9	EPHB1 EPHB2	16 16	MAPK7 (ERK5) MAPKAPK2	22 22	PRKX PTK2 (FAK)	28 28
AMPK (A2/B2/G3) AMPK A1/B1/G1	9	EPHB3	16	MAPKAPK3	22	PTK2B (FAK2)	28
AMPK A2/B1/G1	9	EPHB4	16	MAPKAPK5 (PRAK)	22	PTK6 (Brk)	28
AURKA (Aurora A)	10	ERBB2 (HER2)	16	MARK1 (MARK)	22	RET	29
AURKB (Aurora B)	10	ERBB4 (HER4)	16	MARK2	22	RET A883F	29
AURKC (Aurora C) AXL	10	FER FES (FPS)	16 16	MARK3 MARK4	22 23	RET S891A RET V804E	29 29
BLK	10	FGFR1	16	MATK (HYL)	23	RET V804L	29
BMX	10	FGFR2	16	MELK '	23	RET Y791F	29
BRSK1 (SAD1)	10	FGFR2 N549H	17	MERTK (cMER)	23	ROCK1	29
BTK CAMK1D (CaMKI delta)	10 10	FGFR3 FGFR3 K650E	17 17	MET (cMet) MET (cMet) Y1235D	23 23	ROCK2 ROS1	29 29
CAMK1D (CAMKI delta) CAMK1G (CAMKI gamma)	10	FGFR3 V555M	17	MET (CMET) 11235D MET M1250T	23	RPS6KA1 (RSK1)	29
CAMK2A (CaMKII alpha) CAMK2B (CaMKII beta)	10	FGFR4	17	MINK1	23	RPS6KA2 (RSK3)	29
CAMK2B (CaMKII beta)	11	FGR	17	MKNK1 (MNK1)	23	RPS6KA3 (RSK2)	29
CAMK2D (CaMKII delta)	11	FLT1 (VEGFR1)	17	MST1R (RON)	23	RPS6KA4 (MSK2)	30
CAMK4 (CaMKIV) CDC42 BPA (MRCKA)	11 11	FLT3 FLT3 D835Y	17 17	MS14 MUSK	23 24	RPS6KA5 (MSK1) RPS6KA6 (RSK4)	30 30
CDC42 BPB (MRCKB)	11	FLT4 (VEGFR3)	17	MYLK2 (skMLCK)	24	RPS6KB1 (p70S6K)	30
CDC42 BPG (MRCKG)	11	FRAP1 (mTOR)	18	NEK1	24	SBK1	30
CDK1/cyclin B	11	FRK (PTK5)	18	NEK2	24	SGK (SGK1)	30
CDK17/cyclin Y CDK18/cyclin Y	11 11	FYN GRK4	18 18	NEK4 NEK6	24 24	SGK2 SGKL (SGK3)	30 30
CDK16/Cyclin A	11	GRK5	18	NEK9	24	SNF1LK2	30
CDK5/p25	11	GRK6	18	NIM1K	24	SRC	30
CDK5/p35	12	GRK7	18	NTRK1 (TRKA)	24	SRC N1	30
CDKL5	12	GSK3A (GSK3 alpha) GSK3B (GSK3 beta)	18 18	NTRK2 (TRKB)	24	SRMS (Srm)	31
CHEK1 (CHK1) CHEK2 (CHK2)	12 12	HCK	18	NTRK3 (TRKC) PAK1	24 25	SRPK1 SRPK2	31 31
CLK1	12	HIPK1 (Myak)	18	PAK2 (PAK65)	25	STK22B (TSSK2)	31
CLK2	12	HIPK2	19	PAK3	25	STK22D (TSSK1)	31
CLK3	12	HIPK3 (YAK1)	19	PAK4	25	STK23 (MSSK1)	31
CSF1R (FMS)	12	HIPK4	19	PAK6	25 25	STK24 (MST3) STK25 (YSK1)	31
CSK CSNK1A1 (CK1 alpha 1)	12 12	IGF1R IKBKB (IKK beta)	19 19	PAK7 (KIAA1264) PASK	25 25	STK25 (YSK1) STK3 (MST2)	31 31
CSNK1A1L	12	IKBKE (IKK epsilon)	19	PDGFRA (PDGFR alpha)	25	STK4 (MST1)	31
CSNK1D (CK1 delta)	13	INSR	19	PDGFRA D842V	25	SYK	31
CSNK1E (CK1 epsilon)	13	INSRR (IRR)	19	PDGFRA T674I	25	TAOK2 (TAO1)	32
CSNK1E (CK1 epsilon) R178C CSNK1G1 (CK1 gamma 1)	13 13	IRAK4 ITK	19 19	PDGFRA V561D PDGFRB (PDGFR beta)	25 26	TBK1 TEK (Tie2)	32 32
CSNK1G1 (CK1 gamma 1) CSNK1G2 (CK1 gamma 2)	13	JAK1	19	PDGFRB (PDGFR beta) PDK1 Direct	26	TEK (TIE2) TEK (TIE2) Y897S	32
CSNK1G3 (CK1 gamma 3)	13	JAK2	20	PEAK1	26	TNK1	32 32
CSNK2A1 (CK2 alpha 1)	13	JAK2 JH1 JH2	20	PHKG1	26	TXK	32
CSNK2A2 (CK2 alpha 2)	13	JAK2 JH1 JH2 V617F	20	PHKG2 PIM1	26	TYK2	32
DAPK3 (ZIPK) DCAMKL1 (DCLK1)	13 13	JAK3 KDR (VEGFR2)	20 20	PIM1 PIM2	26 26	TYRO3 (RSE) YES1	32 32
DCAMKL2 (DCK2)	13	KDR (VEGFR2) KIT	20	PIM2 PIM3	26	ZAP70	32
DNA-PK	14	KIT T670I	20	PKN1 (PRK1)	26		32
DYRK1A	14	KIT V559D	20	PLK1 `	26		



SelectScreen™ Biochemical Kinase Profi	ling Service
Z′-LYTE™ Screening Protocol and Assay	Conditions
	Revised 29-Jan-2021
	Page 2 of 40

BRAF	33	MAP2K2 (MEK2)	33	MAPK10 (JNK3)	33	MAPK9 (JNK2)	34
BRAF V599E	33	MAP2K6 (MKK6)	33	MAPK14 (p38 alpha)	33	PDK1	34
MAP2K1 (MEK1)	33	МАРЗК8 (СОТ)	33	MAPK8 (JNK1)	33	RAF1 (cRAF) Y340D Y341D	34



SelectScreen™	Biochemical	Kinase	<b>Profiling</b>	Service
---------------	-------------	--------	------------------	---------

## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 3 of 40

## Assay Theory

The Z´-LYTE biochemical assay employs a fluorescence-based, coupled-enzyme format and is based on the differential sensitivity of phosphorylated and non-phosphorylated peptides to proteolytic cleavage (Figure 1). The peptide substrate is labeled with two fluorophores—one at each end—that make up a FRET pair.

In the primary reaction, the kinase transfers the gamma-phosphate of ATP to a single tyrosine, serine or threonine residue in a synthetic FRET-peptide. In the secondary reaction, a site-specific protease recognizes and cleaves non-phosphorylated FRET-peptides. Phosphorylation of FRET-peptides suppresses cleavage by the Development Reagent. Cleavage disrupts FRET between the donor (i.e., coumarin) and acceptor (i.e., fluorescein) fluorophores on the FRET-peptide, whereas uncleaved, phosphorylated FRET-peptides maintain FRET. A ratiometric method, which calculates the ratio (the Emission Ratio) of donor emission to acceptor emission after excitation of the donor fluorophore at 400 nm, is used to quantitate reaction progress, as shown in the equation below.

Emission Ratio = Coumarin Emission (445 nm)
Fluorescein Emission (520 nm)

A significant benefit of this ratiometric method for quantitating reaction progress is the elimination of well-to-well variations in FRET-peptide concentration and signal intensities. As a result, the assay yields very high Z'-factor values (>0.7) at a low percent phosphorylation.

Both cleaved and uncleaved FRET-peptides contribute to the fluorescence signals and therefore to the Emission Ratio. The extent of phosphorylation of the FRET-peptide can be calculated from the Emission Ratio. The Emission Ratio will remain low if the FRET-peptide is phosphorylated (i.e., no kinase inhibition) and will be high if the FRET-peptide is non-phosphorylated (i.e., kinase inhibition).




Figure 1: Z'-LYTE Illustration



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 4 of 40

## **Z'-LYTE Assay Conditions**

### **Test Compounds**

The Test Compounds are screened in 1% DMSO (final) in the well. For 10 point titrations, 3-fold serial dilutions are conducted from the starting concentration of the customer's choosing.

#### Peptide/Kinase Mixtures

All Peptide/Kinase Mixtures are diluted to a 2X working concentration in the appropriate Kinase Buffer (see section *Kinase Specific Assay Conditions* for a complete description).

#### **ATP Solution**

All ATP Solutions are diluted to a 4X working concentration in Kinase Buffer (50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl<sub>2</sub>, 1 mM EGTA).

ATP Km apparent is previously determined using a Z´-LYTE assay.

#### **Development Reagent Solution**

The Development Reagent is diluted in Development Buffer (see section *Kinase-Specific Assay Conditions - Direct and Cascade* for a complete description).

**10X Novel PKC Lipid Mix:** 2 mg/ml Phosphatidyl Serine, 0.2 mg/ml DAG in 20 mM HEPES, pH 7.4, 0.3% CHAPS

#### For 5 mL 10X Novel PKC Lipid Mix:

- 1. Add 10 mgs Phosphatidyl Serine (Avanti Polar Lipids Part# 8400032C or 840039C) and 1 mg DAG (Avanti Polar Lipids Part# 800811C) to a glass tube.
- 2. Remove the chloroform from lipid mixture by evaporating to a clear, thin film under a stream of nitrogen. Continuous rotation of the tube, at an angle to ensure maximum surface area of the lipid solution, will promote the thinnest film.
- 3. Add 5 mLs resuspension buffer, 20 mM HEPES, 0.3% CHAPS, pH 7.4, to the dried lipid mix
- 4. Heat gently to 50-60 °C for 1-2 minutes and vortex in short intervals until the lipids are dissolved to a clear or slightly hazy solution. The lipids are typically in solution after 2-3 heat/vortex cycles.
- 5. Cool to room temperature, aliquot into single use volumes and store at -20 °C.

#### **Assay Protocol**

Bar-coded Corning, low volume NBS, black 384-well plate (Corning Cat. #4514)

- 1. 100 nL 100X Test Compound in 100% DMSO
- 2. 2.4 μL Kinase buffer
- 3. 5 μL 2X Peptide/Kinase Mixture
- 4. 2.5 µL 4X ATP Solution
- 5. 30-second plate shake
- 6. 60-minute Kinase Reaction incubation at room temperature
- 7. 5 μL Development Reagent Solution
- 8. 30-second plate shake
- 9. 60-minute Development Reaction incubation at room temperature
- 10. Read on fluorescence plate reader and analyze the data



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 5 of 40

## Z'-LYTE Assay Controls

The following controls are made for each individual kinase and are located on the same plate as the kinase:

#### 0% Phosphorylation Control (100% Inhibition Control)

The maximum Emission Ratio is established by the 0% Phosphorylation Control (100% Inhibition Control), which contains no ATP and therefore exhibits no kinase activity. This control yields 100% cleaved peptide in the Development Reaction.

#### 100% Phosphorylation Control

The 100% Phosphorylation Control, which consists of a synthetically phosphorylated peptide of the same sequence as the peptide substrate, is designed to allow for the calculation of percent phosphorylation. This control yields a very low percentage of cleaved peptide in the Development Reaction.

The 0% Phosphorylation and 100% Phosphorylation Controls allow one to calculate the percent Phosphorylation achieved in a specific reaction well. Control wells do not include any kinase inhibitors.

#### 0% Inhibition Control

The minimum Emission Ratio in a screen is established by the 0% Inhibition Control, which contains active kinase. This control is designed to produce a 10–50%\* phosphorylated peptide in the Kinase Reaction.

#### Known Inhibitor

A known inhibitor control standard curve, 10 point titration, is run for each individual kinase on the same plate as the kinase to ensure the kinase is inhibited within an expected IC<sub>50</sub> range previously determined.

The following controls are prepared for each concentration of Test Compound assayed:

#### **Development Reaction Interference**

The Development Reaction Interference is established by comparing the Test Compound Control wells that do not contain ATP versus the 0% Phosphorylation Control (which does not contain the Test Compound). The expected value for a non-interfering compound should be 100%. Any value outside of 90% to 110% is flagged.

#### **Test Compound Fluorescence Interference**

The Test Compound Fluorescence Interference is determined by comparing the Test Compound Control wells that do not contain the Kinase/Peptide Mixture (zero peptide control) versus the 0% Inhibition Control. The expected value for a non-fluorescence compound should be 0%. Any value > 20% is flagged.

<sup>\*</sup> Cascade assays may produce up to 70% phosphorylated peptide.



SelectScreen™ Biochen	nical Kinase	<b>Profiling</b>	Service
-----------------------	--------------	------------------	---------

## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 6 of 40

## Z'-LYTE Data Analysis

The following equations are used for each set of data points:

	Equation
Correction for Background Fluorescence	FI Sample – FI TCFI Ctl
Emission Ratio (using values corrected for background fluorescence)	Coumarin Emission (445 nm)  Fluorescein Emission (520 nm)
% Phosphorylation (% Phos)	$\left\{ 1 - \frac{(\text{Emission Ratio x F}_{100\%}) - C_{100\%}}{(C_{0\%} - C_{100\%}) + [\text{Emission Ratio x (F}_{100\%} - F_{0\%})]} \right\} * 100$
% Inhibition	\[ \begin{pmatrix} \ 1 - \frac{\\ \% \text{Phos} \text{Sample}}{\\ \% \text{Phos} \text{0\% Inhibition Ctl}} \end{pmatrix} \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \
<b>Z</b> ' (using Emission Ratio values)	1 -   3*Stdev 0% Phos Ctl + 3*Stdev 0% Inhibition  Mean 0%Phos Ctl - Mean 0% Inhibition
Difference Between Data Points (single point only)	% Inhibition Point 1 - % Inhibition Point 2
Development Reaction Interference (DRI) (no ATP control)	Emission Ratio DRI Ctl Emission Ratio 0% Phos Ctl
Test Compound Fluorescence Interference (TCFI) (check both Coumarin and Fluorescein emissions)	FI TCFI Ctl FI 0% Inhibitor Ctl

**FI** = Fluorescence Intensity

C<sub>100%</sub> = Average Coumarin emission signal of the 100% Phos. Control

**C**<sub>0%</sub> = Average Coumarin emission signal of the 0% Phos. Control

 $\mathbf{F}_{100\%}$  = Average Fluorescein emission signal of the 100% Phos. Control

 $\mathbf{F}_{0\%}$  = Average Fluorescein emission signal of the 0% Phos. Control

**DRI** = Development Reaction Interference

**TCFI** = Test Compound Fluorescence Interference

#### **Graphing Software**

SelectScreen Kinase Profiling Service uses XLfit from IDBS. The dose response curve is curve fit to model number 205 (sigmoidal dose-response model). If the bottom of the curve does not fit



SelectScreen™ Biochemical Kinase Profi	ling Service
Z'-LYTE™ Screening Protocol and Assay	Conditions
	Revised 29-Jan-2021
	Page 7 of 40

between -20% & 20% inhibition, it is set to 0% inhibition. If the top of the curve does not fit between 70% and 130% inhibition, it is set to 100% inhibition.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 8 of 40

## Kinase-Specific Assay Conditions - Direct Format

#### ABL1

The 2X ABL1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.3 - 1.2 ng ABL1 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### **ABL1 E255K**

The 2X ABL1 E255K / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.75 - 3.74 ng ABL1 E255K and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### **ABL1 F317I**

The 2X ABL1 F317I / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.65 - 8 ng ABL1 F317I and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### **ABL1 F317L**

The 2X ABL1 F317L / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.5 - 5 ng ABL1 F317L and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### **ABL1 G250E**

The 2X ABL1 G250E / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1 - 5 ng ABL1 G250E and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### **ABL1 T315I**

The 2X ABL1 T315I / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.36 - 6 ng ABL1 T315I and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### **ABL1 Y253F**

The 2X ABL1 Y253F / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.73 - 5.76 ng ABL1 Y253F and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### ABL2 (Arg)

The 2X  $\overline{ABL2}$  (Arg) / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.42 - 3.13 ng ABL2 (Arg) and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### ACVR1B (ALK4)

The 2X ACVR1B (ALK4) / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 9.15 - 54 ng ACVR1B (ALK4) and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### ADRBK1 (GRK2)

The 2X ADRBK1 (GRK2) / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.5 - 67.2 ng ADRBK1 (GRK2) and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### ADRBK2 (GRK3)

The 2X ADRBK2 (GRK3) / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4 - 39.2 ng ADRBK2 (GRK3) and 2 μM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 9 of 40

AKT1 (PKB alpha)

The 2X AKT1 (PKB alpha) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.66 - 2.64 ng AKT1 (PKB alpha) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X AKT2 (PKB beta) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.38 - 5.5 ng AKT2 (PKB beta) and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X AKT3 (PKB gamma) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.62 - 2.5 ng AKT3 (PKB gamma) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

ALK
The 2X ALK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.25 - 30 ng ALK and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

#### AMPK (A1/B2/G2)

The 2X AMPK (A1/B2/G2) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1 - 4 ng AMPK (A1/B2/G2) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### AMPK (A1/B2/G3)

The 2X AMPK (A1/B2/G3) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.77 - 5.2 ng AMPK (A1/B2/G3) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### AMPK (A2/B1/G2)

The 2X AMPK (A2/B1/G2) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.66 - 5.24 ng AMPK (A2/B1/G2) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### AMPK (A2/B1/G3)

The 2X AMPK (A2/B1/G3) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.48 - 9.42 ng AMPK (A2/B1/G3) and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### AMPK (A2/B2/G3)

The 2X AMPK (A2/B2/G3) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 1.19 - 6 ng AMPK (A2/B2/G3) and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### AMPK A1/B1/G1

The 2X AMPK A1/B1/G1 / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.21 - 1.07 ng AMPK A1/B1/G1 and 2 µM Ser/Thr 23 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X AMPK A2/B1/G1 / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.5 - 7 ng AMPK A2/B1/G1 and 2 μM Ser/Thr 23 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 10 of 40

#### AURKA (Aurora A)

The 2X AURKA (Aurora A) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.75 - 3 ng AURKA (Aurora A) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### AURKB (Aurora B)

The 2X AURKB (Aurora B) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.5 - 18 ng AURKB (Aurora B) and 2 µM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### AURKC (Aurora C)

The 2X AURKC (Aurora C) / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2 - 20 ng AURKC (Aurora C) and 2 µM Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

#### <u>AXL</u>

The 2X AXL / Tyr 06 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 2 - 12 ng AXL and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### **BLK**

The 2X BLK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.08 - 0.33 ng BLK and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### **BMX**

The 2X BMX / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2.5 - 10 ng BMX and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### BRSK1 (SAD1)

The 2X BRSK1 (SAD1) / Ser/Thr 21 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2.8 - 28.6 ng BRSK1 (SAD1) and 2  $\mu$ M Ser/Thr 21 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### BTK

The 2X BTK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.52 - 3.36 ng BTK and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

#### CAMK1D (CaMKI delta)

The 2X CAMK1D (CaMKI delta) / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 12.5 - 50 ng CAMK1D (CaMKI delta) and 2  $\mu$ M Ser/Thr 25 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### **CAMK1G (CAMKI gamma)**

The 2X CAMK1G (CAMKI gamma) / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 7.5 - 30 ng CAMK1G (CAMKI gamma) and 2 µM Ser/Thr 23 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### CAMK2A (CaMKII alpha)

The 2X CAMK2A (CaMKII alpha) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 0.27 - 2.8 ng CAMK2A (CaMKII alpha) and 2 µM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 11 of 40

CAMK2B (CaMKII beta)

The 2X CAMK2B (CaMKII beta) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 0.1 - 0.7 ng CAMK2B (CaMKII beta) and 2  $\mu$ M Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:256 dilution of Development Reagent A is added.

#### CAMK2D (CaMKII delta)

The 2X CAMK2D (CaMKII delta) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.08 - 0.67 ng CAMK2D (CaMKII delta) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### **CAMK4 (CaMKIV)**

The 2X CAMK4 (CaMKIV) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 8 - 90 ng CAMK4 (CaMKIV) and 2  $\mu$ M Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### CDC42 BPA (MRCKA)

The 2X CDC42 BPA (MRCKA) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 9.75 - 45.5 ng CDC42 BPA (MRCKA) and 2 µM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### CDC42 BPB (MRCKB)

The 2X CDC42 BPB (MRCKB) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 4.35 - 21.7 ng CDC42 BPB (MRCKB) and 2 µM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### CDC42 BPG (MRCKG)

The 2X CDC42 BPG (MRCKG) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.5 - 34 ng CDC42 BPG (MRCKG) and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### CDK1/cyclin B

The 2X CDK1/cyclin B / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 3.5 - 15 ng CDK1/cyclin B and 2  $\mu$ M Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### CDK17/cyclin Y

The 2X CDK17/cyclin Y / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2.88 - 14 ng CDK17/cyclin Y and 2  $\mu$ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### CDK18/cyclin Y

The 2X CDK18/cyclin Y / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1.46 - 6.84 ng CDK18/cyclin Y and 2  $\mu$ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### CDK2/cyclin A

The 2X CDK2/cyclin A / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1.22 - 11.6 ng CDK2/cyclin A and 2  $\mu$ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### CDK5/p25

The 2X CDK5/p25 / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.25 - 1 ng CDK5/p25 and 2  $\mu$ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 12 of 40

#### CDK5/p35

The 2X CDK5/p35 / Ser/Thr 12 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.14 - 1.3 ng CDK5/p35 and 2  $\mu$ M Ser/Thr 12 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### CDKI 5

The 2X CDKL5 / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 10 - 40 ng CDKL5 and 2 µM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### CHEK1 (CHK1)

The 2X CHEK1 (CHK1) / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.38 - 12 ng CHEK1 (CHK1) and 2 μM Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### CHEK2 (CHK2)

The 2X CHEK2 (CHK2) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 5.51 - 40 ng CHEK2 (CHK2) and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### CLK1

The 2X CLK1 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 30 - 120 ng CLK1 and 2 µM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:512 dilution of Development Reagent A is added.

#### CLK2

The 2X CLK2 / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.97 - 10.4 ng CLK2 and 2  $\mu$ M Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### CLK3

The ZX CLK3 / Ser/Thr 18 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 9.57 - 38.3 ng CLK3 and 2  $\mu$ M Ser/Thr 18 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### CSF1R (FMS)

The 2X CSF1R (FMS) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.3 - 2.5 ng CSF1R (FMS) and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### CSK

The 2X CSK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.5 - 35.4 ng CSK and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### CSNK1A1 (CK1 alpha 1)

The 2X CSNK1A1 (CK1 alpha 1) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 3.38 - 13.5 ng CSNK1A1 (CK1 alpha 1) and 2 μM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### CSNK1A1L

The 2X CSNK1A1L / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 8.75 - 40 ng CSNK1A1L and 2  $\mu$ M Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:16 dilution of Development Reagent B is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 13 of 40

#### CSNK1D (CK1 delta)

The 2X CSNK1D (CK1 delta) / Ser/Thr 11 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 9.97 - 49 ng CSNK1D (CK1 delta) and 2 µM Ser/Thr 11 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### CSNK1E (CK1 epsilon)

The 2X CSNK1E (CK1 epsilon) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.35 - 9.44 ng CSNK1E (CK1 epsilon) and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

CSNK1E (CK1 epsilon) R178C
The 2X CSNK1E (CK1 epsilon) R178C / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3.75 - 25 ng CSNK1E (CK1 epsilon) R178C and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### CSNK1G1 (CK1 gamma 1)

The 2X CSNK1G1 (CK1 gamma 1) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.75 - 8.16 ng CSNK1G1 (CK1 gamma 1) and 2 μM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### CSNK1G2 (CK1 gamma 2)

The 2X CSNK1G2 (CK1 gamma 2) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2 - 8 ng CSNK1G2 (CK1 gamma 2) and 2 µM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### CSNK1G3 (CK1 gamma 3)

The 2X CSNK1G3 (CK1 gamma 3) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.25 - 17.5 ng CSNK1G3 (CK1 gamma 3) and 2 μM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### CSNK2A1 (CK2 alpha 1)

The 2X CSNK2A1 (CK2 alpha 1) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 6.41 - 25.7 ng CSNK2A1 (CK2 alpha 1) and 2 µM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### CSNK2A2 (CK2 alpha 2)

The 2X CSNK2A2 (CK2 alpha 2) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.6 - 12 ng CSNK2A2 (CK2 alpha 2) and 2 μM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### DAPK3 (ZIPK)

The 2X DAPK3 (ZIPK) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 6.79 - 34.4 ng DAPK3 (ZIPK) and 2 µM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### DCAMKL1 (DCLK1)

The 2X DCAMKL1 (DCLK1) / Ser/Thr 23 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.75 - 15 ng DCAMKL1 (DCLK1) and 2 μM Ser/Thr 23 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 14 of 40

#### DCAMKL2 (DCK2)

The 2X DCAMKL2 (DCK2) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 8.8 - 35.2 ng DCAMKL2 (DCK2) and 2 μM Ser/Thr 17 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### **DNA-PK**

The 2X DNA-PK / Ser/Thr 26 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT, 5.0 μg/ml CT-DNA. The final 10 μL Kinase Reaction consists of 3.88 - 16 ng DNA-PK and 2 μM Ser/Thr 26 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT, 2.5 μg/ml CT-DNA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### DYRK1A

The 2X DYRK1A / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.77 - 3.08 ng DYRK1A and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### DYRK1B

The 2X DYRK1B / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 0.59 - 2.37 ng DYRK1B and 2  $\mu$ M Ser/Thr 18 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### DYRK3

The 2X DYRK3 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 3 - 12 ng DYRK3 and 2 µM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:512 dilution of Development Reagent A is added.

#### DYRK4

The 2X DYRK4 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 6.25 - 52 ng DYRK4 and 2 µM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:512 dilution of Development Reagent A is added.

#### EEF2K

The  $\overline{2X}$  EEF2K / Ser/Thr 24 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 5.97 - 44 ng EEF2K and 2  $\mu$ M Ser/Thr 24 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:16384 dilution of Development Reagent A is added.

#### EGFR (ErbB1)

The 2X EGFR (ErbB1) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2 - 8 ng EGFR (ErbB1) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) C797S

The 2X EGFR (ErbB1) C797S / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 2.5 - 14 ng EGFR (ErbB1) C797S and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) G719C

The 2X EGFR (ErbB1) G719C / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 2.5 - 25 ng EGFR (ErbB1) G719C and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 15 of 40

#### EGFR (ErbB1) G719S

The 2X EGFR (ErbB1) G719S / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.82 - 3.3 ng EGFR (ErbB1) G719S and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) L858R

The 2X EGFR (ErbB1) L858R / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.18 - 0.82 ng EGFR (ErbB1) L858R and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) L861Q

The 2X EGFR (ErbB1) L861Q / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10  $\mu$ L Kinase Reaction consists of 2.31 - 11.2 ng EGFR (ErbB1) L861Q and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) T790M

The 2X EGFR (ErbB1) T790M / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 3.9 - 20 ng EGFR (ErbB1) T790M and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) T790M C797S L858R

The 2X EGFR (ErbB1) T790M C797S L858R / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10  $\mu$ L Kinase Reaction consists of 1.25 - 8 ng EGFR (ErbB1) T790M C797S L858R and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### EGFR (ErbB1) T790M L858R

The 2X EGFR (ErbB1) T790M L858R / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.12 - 1 ng EGFR (ErbB1) T790M L858R and 2 μM Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### EPHA1

The 2X EPHA1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.12 - 38.6 ng EPHA1 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### EPHA2

The 2X EPHA2 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.1 - 8.8 ng EPHA2 and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### EPHA4

The 2X EPHA4 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 5.42 - 21.7 ng EPHA4 and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### EPHA5

The 2X EPHA5 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.18 - 7.5 ng EPHA5 and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 16 of 40

#### EPHA8

The 2X EPHA8 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.2 - 4.8 ng EPHA8 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### EPHB1

The 2X EPHB1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.39 - 10 ng EPHB1 and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### EPHB2

The 2X EPHB2 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.55 - 2.86 ng EPHB2 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### EPHB3

The 2X EPHB3 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.78 - 7.8 ng EPHB3 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### EPHB4

The 2X EPHB4 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.68 - 2.72 ng EPHB4 and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### ERBB2 (HER2)

The 2X ERBB2 (HER2) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 6 - 24 ng ERBB2 (HER2) and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### ERBB4 (HER4)

The 2X ERBB4 (HER4) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 5 - 20 ng ERBB4 (HER4) and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

#### <u>FER</u>

The 2X FER / Tyr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.79 - 4 ng FER and 2 μM Tyr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### FES (FPS

The 2X FES (FPS) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.65 - 2.8 ng FES (FPS) and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

#### FGFR1

The 2X FGFR1 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 0.88 - 3.5 ng FGFR1 and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### FGFR2

The 2X FGFR2 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.19 - 1.99 ng FGFR2 and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 17 of 40

#### FGFR2 N549H

The 2X FGFR2 N549H / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.55 - 6 ng FGFR2 N549H and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### FGFR3

The 2X FGFR3 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 0.45 - 4.5 ng FGFR3 and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### FGFR3 K650E

The 2X FGFR3 K650E / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.6 - 6 ng FGFR3 K650E and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### FGFR3 V555M

The 2X FGFR3 V555M / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1.5 - 10 ng FGFR3 V555M and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### FGFR4

The 2X FGFR4 / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 4.5 - 20 ng FGFR4 and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### FGR

The 2X FGR / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.75 - 8 ng FGR and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### FLT1 (VEGFR1)

The 2X FLT1 (VEGFR1) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2.64 - 10.6 ng FLT1 (VEGFR1) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### FLT3

The 2X FLT3 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.4 - 3.88 ng FLT3 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### FLT3 D835Y

The 2X FLT3 D835Y / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.08 - 1.2 ng FLT3 D835Y and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### FLT4 (VEGFR3)

The 2X FLT4 (VEGFR3) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2.29 - 16 ng FLT4 (VEGFR3) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 18 of 40

#### FRAP1 (mTOR)

The 2X FRAP1 (mTOR) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 10 - 80 ng FRAP1 (mTOR) and 2 μM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### FRK (PTK5)

The 2X FRK (PTK5) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.1 - 8 ng FRK (PTK5) and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### **FYN**

The 2X FYN / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.44 - 17.8 ng FYN and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### GRK4

The 2X GRK4 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.28 - 3.76 ng GRK4 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### GRK5

The 2X GRK5 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 4 - 16.9 ng GRK5 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### GRK

The 2X GRK6 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 5 - 44.6 ng GRK6 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### **GRK7**

The 2X GRK7 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2 - 19.5 ng GRK7 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### GSK3A (GSK3 alpha)

The 2X GSK3A (GSK3 alpha) / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.21 - 1.69 ng GSK3A (GSK3 alpha) and 2 μM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:512 dilution of Development Reagent A is added.

#### GSK3B (GSK3 beta)

The 2X GSK3B (GSK3 beta) / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.12 - 0.8 ng GSK3B (GSK3 beta) and 2  $\mu$ M Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:512 dilution of Development Reagent A is added.

#### <u>HCK</u>

The 2X HCK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.22 - 1.4 ng HCK and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### HIPK1 (Myak)

The 2X HIPK1 (Myak) / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2.48 - 23.4 ng HIPK1 (Myak) and 2  $\mu$ M Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:512 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 19 of 40

#### HIPK2

The 2X HIPK2 / Ser/Thr 09 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.53 - 19 ng HIPK2 and 2 μM Ser/Thr 09 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:512 dilution of Development Reagent A is added.

#### HIPK3 (YAK1)

The 2X HIPK3 (YAK1) / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 8.75 - 40 ng HIPK3 (YAK1) and 2  $\mu$ M Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### HIPK4

The 2X HIPK4 / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.16 - 12 ng HIPK4 and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### **IGF1R**

The 2X IGF1R / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 6 - 50 ng IGF1R and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### IKBKB (IKK beta)

The 2X IKBKB (IKK beta) / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.62 - 4 ng IKBKB (IKK beta) and 2 μM Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### IKBKE (IKK epsilon)

The 2X IKBKE (IKK epsilon) / Ser/Thr 11 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.82 - 10.6 ng IKBKE (IKK epsilon) and 2 μM Ser/Thr 11 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:16 dilution of Development Reagent B is added.

#### **INSR**

The 2X INSR / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 1.94 - 9.32 ng INSR and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### INSRR (IRR)

The 2X INSRR (IRR) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2.19 - 9.4 ng INSRR (IRR) and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### **IRAK4**

The 2X IRAK4 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 3.45 - 20 ng IRAK4 and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### <u>ITK</u>

The 2X ITK / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.69 - 60 ng ITK and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### JAK1

The 2X JAK1 / Tyr 06 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 22.9 - 91.5 ng JAK1 and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 20 of 40

#### JAK2

The 2X JAK2 / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.12 - 0.5 ng JAK2 and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### JAK2 JH1 JH2

The 2X JAK2 JH1 JH2 / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.75 - 5.12 ng JAK2 JH1 JH2 and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### JAK2 JH1 JH2 V617F

The 2X JAK2 JH1 JH2 V617F / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.75 - 9 ng JAK2 JH1 JH2 V617F and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### JAK3

The 2X JAK3 / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.5 - 2.7 ng JAK3 and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### KDR (VEGFR2)

The 2X KDR (VEGFR2) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2 - 8 ng KDR (VEGFR2) and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### **KIT**

The 2X KIT / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.17 - 12.7 ng KIT and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### **KIT T670**I

The 2X KIT T670I / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 3 - 16.8 ng KIT T670I and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### **KIT V559D**

The 2X KIT V559D / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 3.64 - 30 ng KIT V559D and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### KIT V559D V654A

The 2X KIT V559D V654A / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 8.75 - 50 ng KIT V559D V654A and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### **KIT V560G**

The 2X KIT V560G / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 5 - 40 ng KIT V560G and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### KSR2

The 2X KSR2 / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1.06 - 6 ng KSR2 and 2  $\mu$ M Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:256 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 21 of 40

#### **LCK**

The 2X LCK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 8 - 33 ng LCK and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

The 2X LTK (TYK1) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.78 - 13.1 ng LTK (TYK1) and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

The  $\overline{ ext{2X}}$  LYN A / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.88 - 7 ng LYN A and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

LYN B
The 2X LYN B / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.89 - 6.8 ng LYN B and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### **MAP3K19 (YSK4)**

The 2X MAP3K19 (YSK4) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.06 - 8 ng MAP3K19 (YSK4) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### MAP3K9 (MLK1)

The 2X MAP3K9 (MLK1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 5 - 20 ng MAP3K9 (MLK1) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### MAP4K2 (GCK)

The 2X MAP4K2 (GCK) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.5 - 2 ng MAP4K2 (GCK) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1.45000 dilution of Development Reagent A is added.

The 2X MAP4K4 (HGK) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.36 - 4 ng MAP4K4 (HGK) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1.45000 dilution of Development Reagent A is added.

The 2X MAP4K5 (KHS1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.75 - 4 ng MAP4K5 (KHS1) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### MAPK1 (ERK2)

The 2X MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2 - 8 ng MAPK1 (ERK2) and 2 µM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### MAPK11 (p38 beta)

The 2X MAPK11 (p38 beta) / Ser/Thr 15 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 7.1 - 28.4 ng MAPK11 (p38 beta) and 2 µM Ser/Thr 15 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 22 of 40

#### MAPK12 (p38 gamma)

The 2X MAPK12 (p38 gamma) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.81 - 3.26 ng MAPK12 (p38 gamma) and 2 µM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### MAPK13 (p38 delta)

The 2X MAPK13 (p $\overline{9}$ 8 delta) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 6.25 - 25 ng MAPK13 (p $\overline{9}$ 8 delta) and 2  $\mu$ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### MAPK14 (p38 alpha) Direct

The 2X MAPK14 (p38 alpha) / Ser/Thr 15 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 7.07 - 28.3 ng MAPK14 (p38 alpha) and 2  $\mu$ M Ser/Thr 15 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### MAPK3 (ERK1)

The 2X MAPK3 (ERK1) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 12.5 - 50 ng MAPK3 (ERK1) and 2  $\mu$ M Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### MAPK7 (ERK5)

The 2X MAPK7 (ERK5) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.75 - 4 ng MAPK7 (ERK5) and 2  $\mu$ M Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### MAPKAPK2

The 2X MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.04 - 0.16 ng MAPKAPK2 and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### **MAPKAPK3**

The 2X MAPKAPK3 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.08 - 0.45 ng MAPKAPK3 and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MAPKAPK5 (PRAK)

The 2X MAPKAPK5 (PRAK) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.13 - 5.14 ng MAPKAPK5 (PRAK) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MARK1 (MARK)

The 2X MARK1 (MARK) / Ser/Thr 21 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 14.9 - 168 ng MARK1 (MARK) and 2 µM Ser/Thr 21 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### MARK2

The 2X MARK2 / Ser/Thr 21 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 37.2 - 149 ng MARK2 and 2  $\mu$ M Ser/Thr 21 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### MARK3

The 2X MARK3 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.32 - 1.82 ng MARK3 and 2  $\mu$ M Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 23 of 40

#### MARK4

The 2X MARK4 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.54 - 2.36 ng MARK4 and 2 μM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### MATK (HYL)

The 2X MATK (HYL) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 4.06 - 39 ng MATK (HYL) and 2 µM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent B is added.

#### MELK

The 2X MELK / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.76 - 4.32 ng MELK and 2 µM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

#### MERTK (cMER)

The 2X MERTK (cMER) / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.68 - 6.22 ng MERTK (cMER) and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### MET (cMet)

The 2X MET (cMet) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1 - 4 ng MET (cMet) and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### MET (cMet) Y1235D

The 2X MET (cMet) Y1235D / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.55 - 6 ng MET (cMet) Y1235D and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### **MET M1250T**

The 2X MET M1250T / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3 - 16.2 ng MET M1250T and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### MINK1

The 2X MINK1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.6 - 16 ng MINK1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### MKNK1 (MNK1)

The 2X MKNK1 (MNK1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10  $\mu$ L Kinase Reaction consists of 16 - 63.8 ng MKNK1 (MNK1) and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### MST1R (RON)

The 2X MST1R (RON) / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.25 - 1.18 ng MST1R (RON) and 2  $\mu$ M Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### MST4

The  $\overline{2}X$  MST4 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 12.5 - 50 ng MST4 and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 24 of 40

#### **MUSK**

The 2X MUSK / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 21.3 - 134 ng MUSK and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### MYLK2 (skMLCK)

The 2X MYLK2 (skMLCK) / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.13 - 13 ng MYLK2 (skMLCK) and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### NEK1

The 2X NEK1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.3 - 9.18 ng NEK1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### NEK2

The 2X NEK2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.5 - 4.8 ng NEK2 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### NEK4

The 2X NEK4 / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 4 - 18.1 ng NEK4 and 2 µM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

#### NEK

The 2X NEK6 / Ser/Thr 22 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.13 - 5.5 ng NEK6 and 2 µM Ser/Thr 22 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:8192 dilution of Development Reagent A is added.

#### NEK9

The 2X NEK9 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 1.44 - 5.76 ng NEK9 and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### NIM1K

The 2X NIM1K / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.28 - 20 ng NIM1K and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### NTRK1 (TRKA)

The 2X NTRK1 (TRKA) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 6 - 24 ng NTRK1 (TRKA) and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### NTRK2 (TRKB)

The 2X NTRK2 (TRKB) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.34 - 4 ng NTRK2 (TRKB) and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.

#### NTRK3 (TRKC)

The 2X NTRK3 (TRKC) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2.7 - 30 ng NTRK3 (TRKC) and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 25 of 40

#### PAK1

The 2X PAK1 / Ser/Thr 19 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2.71 - 30.8 ng PAK1 and 2  $\mu$ M Ser/Thr 19 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:256 dilution of Development Reagent A is added.

#### PAK2 (PAK65)

The 2X PAK2 (PAK65) / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.6 - 4.4 ng PAK2 (PAK65) and 2  $\mu$ M Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:256 dilution of Development Reagent A is added.

#### PAK3

The 2X PAK3 / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.38 - 5.5 ng PAK3 and 2 μM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### PAK4

The 2X PAK4 / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.1 - 0.63 ng PAK4 and 2 μM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### PAK6

The 2X PAK6 / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.38 - 9 ng PAK6 and 2 µM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

#### **PAK7 (KIAA1264)**

The 2X PAK7 (KIAA1264) / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.05 - 0.5 ng PAK7 (KIAA1264) and 2 μM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### <u>PASK</u>

The 2X PASK / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.6 - 15.4 ng PASK and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PDGFRA (PDGFR alpha)

The 2X PDGFRA (PDGFR alpha) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10  $\mu$ L Kinase Reaction consists of 5.64 - 22.6 ng PDGFRA (PDGFR alpha) and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### PDGFRA D842V

The 2X PDGFRA D842V / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 3.49 - 18.2 ng PDGFRA D842V and 2 μM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:64 dilution of Development Reagent B is added.

#### PDGFRA T674I

The 2X PDGFRA T674I / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 6.75 - 27 ng PDGFRA T674I and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### PDGFRA V561D

The 2X PDGFRA V561D / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 2 - 10 ng PDGFRA V561D and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 26 of 40

PDGFRB (PDGFR beta)

The 2X PDGFRB (PDGFR beta) / Tyr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 20 - 80 ng PDGFRB (PDGFR beta) and 2 µM Tyr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:64 dilution of Development Reagent B is added.

#### **PDK1 Direct**

The 2X PDK1 / Ser/Thr 07 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 7.5 - 30 ng PDK1 and 2 μM Ser/Thr 07 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PEAK1

The 2X PEAK1 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10  $\mu$ L Kinase Reaction consists of 2.73 - 15 ng PEAK1 and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### PHKG1

The 2X PHKG1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 800 U/ml Calmodulin, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 2.13 - 12.9 ng PHKG1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 400 U/ml Calmodulin, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### PHKG2

The 2X PHKG2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.3 - 10.1 ng PHKG2 and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PIM1

The 2X PIM1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.3 - 1.19 ng PIM1 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### PIM2

The 2X PIM2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1.5 - 6.86 ng PIM2 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### PIM3

The 2X PIM3 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 0.6 - 12.3 ng PIM3 and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### PKN1 (PRK1)

The 2X PKN1 (PRK1) / Ser/Thr 07 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 6 - 39.3 ng PKN1 (PRK1) and 2 µM Ser/Thr 07 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### PLK1

The 2X PLK1 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 2.98 - 26 ng PLK1 and 2 µM Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### PLK<sub>2</sub>

The 2X PLK2 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 3.5 - 14 ng PLK2 and 2  $\mu$ M Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:16 dilution of Development Reagent B is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 27 of 40

#### PLK3

The 2X PLK3 / Ser/Thr 16 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.15 - 1.08 ng PLK3 and 2  $\mu$ M Ser/Thr 16 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:16 dilution of Development Reagent B is added.

#### PRKACA (PKA)

The 2X PRKACA (PKA) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.03 - 0.14 ng PRKACA (PKA) and 2  $\mu$ M Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### PRKCA (PKC alpha)

The 2X PRKCA (PKC alpha) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.12 - 0.7 ng PRKCA (PKC alpha) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PRKCB1 (PKC beta I)

The 2X PRKCB1 (PKC beta I) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.07 - 0.6 ng PRKCB1 (PKC beta I) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PRKCB2 (PKC beta II)

The 2X PRKCB2 (PKC beta II) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.17 - 1.12 ng PRKCB2 (PKC beta II) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PRKCD (PKC delta)

The 2X PRKCD (PKC delta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.75 - 4.2 ng PRKCD (PKC delta) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PRKCE (PKC epsilon)

The 2X PRKCE (PKC epsilon) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 1.21 - 6.66 ng PRKCE (PKC epsilon) and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### PRKCG (PKC gamma)

The 2X PRKCG (PKC gamma) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 0.38 - 2.49 ng PRKCG (PKC gamma) and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### PRKCH (PKC eta)

The 2X PRKCH (PKC eta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 0.3 - 1.6 ng PRKCH (PKC eta) and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### PRKCI (PKC iota)

The 2X PRKCI (PKC iota) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 1.25 - 6 ng PRKCI (PKC iota) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 28 of 40

#### PRKCN (PKD3)

The 2X PRKCN (PKD3) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.25 - 32 ng PRKCN (PKD3) and 2 μM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### PRKCQ (PKC theta)

The 2X PRKCQ (PKC theta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 0.03 - 0.1 ng PRKCQ (PKC theta) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PRKCZ (PKC zeta)

The 2X PRKCZ (PKC zeta) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 4 mM CaCl2, 2X Novel Lipid Mix, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.02 - 12.7 ng PRKCZ (PKC zeta) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM CaCl2, 1X Novel Lipid Mix, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### PRKD1 (PKC mu)

The 2X PRKD1 (PKC mu) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.56 - 7.8 ng PRKD1 (PKC mu) and 2 µM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

#### PRKD2 (PKD2)

The 2X PRKD2 (PKD2) / Ser/Thr 17 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.3 - 1.6 ng PRKD2 (PKD2) and 2 μM Ser/Thr 17 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:256 dilution of Development Reagent A is added.

#### PRKG1

The 2X PRKG1 / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 20 μM cGMP. The final 10 μL Kinase Reaction consists of 0.17 - 0.98 ng PRKG1 and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 10 μM cGMP. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### PRKG2 (PKG2)

The 2X PRKG2 (PKG2) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 20 μM cGMP. The final 10 μL Kinase Reaction consists of 0.1 - 0.4 ng PRKG2 (PKG2) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 10 μM cGMP. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### PRKX

The 2X PRKX / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.75 - 4.98 ng PRKX and 2 µM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### PTK2 (FAK)

The 2X PTK2 (FAK) / Tyr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 25 - 100 ng PTK2 (FAK) and 2 µM Tyr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:16 dilution of Development Reagent B is added.

#### PTK2B (FAK2)

The 2X PTK2B (FAK2) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 5.26 - 34.8 ng PTK2B (FAK2) and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### PTK6 (Brk)

The 2X PTK6 (Brk) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 8.12 - 32.5 ng PTK6 (Brk) and 2 μM Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent B is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 29 of 40

#### **RET**

The 2X RET / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.49 - 3.64 ng RET and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### RET A883F

The 2X RET A883F / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 1.02 - 6.74 ng RET A883F and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### **RET S891A**

The 2X RET S891A / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.3 - 1.4 ng RET S891A and 2 µM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### **RET V804E**

The 2X RET V804E / Tyr 04 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 3 - 20 ng RET V804E and 2  $\mu$ M Tyr 04 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### RET V804L

The 2X RET V804L / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.52 - 4.74 ng RET V804L and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### RET Y791F

The 2X RET Y791F / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.86 - 6.16 ng RET Y791F and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.

#### ROCK1

The 2X ROCK1 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1.73 - 6.92 ng ROCK1 and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### ROCK2

The 2X ROCK2 / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.58 - 2.49 ng ROCK2 and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### ROS1

The  $\overline{2}X$  ROS1 / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 3 - 12 ng ROS1 and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### RPS6KA1 (RSK1)

The 2X RPS6KAT (RSK1) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.51 - 18.5 ng RPS6KA1 (RSK1) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### RPS6KA2 (RSK3)

The 2X RPS6KA2 (RSK3) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.5 - 18 ng RPS6KA2 (RSK3) and 2  $\mu$ M Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.

#### RPS6KA3 (RSK2)

The 2X RPS6KA3 (RSK2) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.1 - 0.48 ng RPS6KA3 (RSK2) and 2  $\mu$ M Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:4096 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 30 of 40

#### RPS6KA4 (MSK2)

The 2X RPS6KA4 (MSK2) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 3.1 - 23.4 ng RPS6KA4 (MSK2) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X RPS6KA5 (MSK1) / Ser/Thr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.23 - 1.35 ng RPS6KA5 (MSK1) and 2 μM Ser/Thr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X RPS6KA6 (RSK4) / Ser/Thr 20 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.1 - 1.4 ng RPS6KA6 (RSK4) and 2 µM Ser/Thr 20 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:256 dilution of Development Reagent A is added.

#### RPS6KB1 (p70S6K)

The 2X RPS6KB1 (p70S6K) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.87 - 17.7 ng RPS6KB1 (p70S6K) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

The 2X SBK1 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 µL Kinase Reaction consists of 2.79 - 30 ng SBK1 and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### SGK (SGK1)

The 2X SGK (SGK1) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.05 - 0.4 ng SGK (SGK1) and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### SGK<sub>2</sub>

The 2X SGK2 / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.21 - 0.96 ng SGK2 and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X SGKL (SGK3) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.19 - 3 ng SGKL (SGK3) and 2 μM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

The 2X SNF1LK2 / Ser/Thr 25 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.62 - 2.74 ng SNF1LK2 and 2 µM Ser/Thr 25 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

 $\frac{\textbf{SRC}}{\textbf{The 2X SRC / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01\% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 <math>\mu$ L Kinase Reaction consists of 5 - 20 ng SRC and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### SRC N1

The 2X SRC N1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1 - 4.88 ng SRC N1 and 2 µM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:128 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 31 of 40

#### SRMS (Srm)

The 2X SRMS (Srm) / Tyr 01 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1.5 - 6 ng SRMS (Srm) and 2  $\mu$ M Tyr 01 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent B is added.

#### SRPK1

The 2X SRPK1 / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 8.1 - 32.4 ng SRPK1 and 2 µM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### SRPK2

The 2X SRPK2 / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 6.5 - 26 ng SRPK2 and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### STK22B (TSSK2)

The 2X STK22B (TSSK2) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.55 - 47.2 ng STK22B (TSSK2) and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### STK22D (TSSK1)

The 2X STK22D (TSSK1) / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 1 - 6.74 ng STK22D (TSSK1) and 2 µM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### STK23 (MSSK1)

The 2X STK23 (MSSK1) / Ser/Thr 18 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 5.69 - 26.2 ng STK23 (MSSK1) and 2 μM Ser/Thr 18 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### STK24 (MST3)

The 2X STK24 (MST3) / Ser/Thr 07 mixture is prepared in 50 mM Tris pH 8.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 10 - 40 ng STK24 (MST3) and 2 μM Ser/Thr 07 in 50 mM Tris / HEPES pH 8.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### STK25 (YSK1)

The 2X STK25 (YSK1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.34 - 12.3 ng STK25 (YSK1) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### STK3 (MST2)

The 2X STK3 (MST2) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 µL Kinase Reaction consists of 5 - 25 ng STK3 (MST2) and 2 µM Ser/Thr 07 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:45000 dilution of Development Reagent A is added.

#### STK4 (MST1)

The 2X STK4 (MST1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 6.25 - 28 ng STK4 (MST1) and 2  $\mu$ M Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:45000 dilution of Development Reagent A is added.

#### <u>SYK</u>

The 2X SYK / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.3 - 1.4 ng SYK and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 32 of 40

#### TAOK2 (TAO1)

The 2X TAOK2 (TAO1) / Ser/Thr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 2.4 - 9.6 ng TAOK2 (TAO1) and 2 μM Ser/Thr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:45000 dilution of Development Reagent A is added.

#### TBK1

The  $\overline{2}X$  TBK1 / Ser/Thr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.93 - 11 ng TBK1 and 2  $\mu$ M Ser/Thr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:64 dilution of Development Reagent B is added.

#### TEK (Tie2)

The 2X TEK (Tie2) / Tyr 05 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 4 mM MnCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2 - 18 ng TEK (Tie2) and 2 μM Tyr 05 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 2 mM MnCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### **TEK (TIE2) Y897S**

The 2X TEK (TIE2) Y897S / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.38 - 3 ng TEK (TIE2) Y897S and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### TNK1

The 2X TNK1 / Ser/Thr 13 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 15 - 60 ng TNK1 and 2 μM Ser/Thr 13 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### TXK

The 2X TXK / Tyr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 4.75 - 19 ng TXK and 2 μM Tyr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### TYK2

The 2X TYK2 / Tyr 03 mixture is prepared in 50 mM HEPES pH 6.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.02% NaN3. The final 10 μL Kinase Reaction consists of 3.75 - 15 ng TYK2 and 2 μM Tyr 03 in 50 mM HEPES pH 7.0, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:4096 dilution of Development Reagent A is added.

#### TYRO3 (RSE)

The 2X TYRO3 (RSE) / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 1.08 - 8 ng TYRO3 (RSE) and 2  $\mu$ M Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:128 dilution of Development Reagent A is added.

#### YES1

The 2X YES1 / Tyr 02 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.75 - 6 ng YES1 and 2 μM Tyr 02 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:128 dilution of Development Reagent A is added.

#### **ZAP70**

The 2X ZAP70 / Tyr 07 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MnCl2, 1 mM EGTA, 2 mM DTT, 0.02% NaN3. The final 10  $\mu$ L Kinase Reaction consists of 20.3 - 126 ng ZAP70 and 2  $\mu$ M Tyr 07 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 5 mM MgCl2, 5 mM MnCl2, 1 mM EGTA, 1 mM DTT, 0.01% NaN3. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:16 dilution of Development Reagent B is added.



#### Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 33 of 40

## Kinase-Specific Assay Conditions - Cascade Format

#### **BRAI**

The 2X BRAF / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.14 - 0.56 ng BRAF, 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 µM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.

#### **BRAF V599E**

The 2X BRAF V599E / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.003 - 0.01 ng BRAF V599E, 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MAP2K1 (MEK1)

The 2X MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.12 - 0.5 ng MAP2K1 (MEK1), 105 ng inactive MAPK1 (ERK2), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MAP2K2 (MEK2)

The 2X MAP2K2 (MEK2) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.25 - 1 ng MAP2K2 (MEK2), 105 ng inactive MAPK1 (ERK2), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MAP2K6 (MKK6)

The 2X MAP2K6 (MKK6) / inactive MAPK12 (p38 gamma) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 1.92 - 7.67 ng MAP2K6 (MKK6), 100 ng inactive MAPK12 (p38 gamma), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MAP3K8 (COT)

The 2X MAP3K8 (COT) / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 μL Kinase Reaction consists of 0.95 - 3.8 ng MAP3K8 (COT), 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 μM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### MAPK10 (JNK3)

The 2X MAPK10 (JNK3) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10  $\mu$ L Kinase Reaction consists of 0.96 - 3.86 ng MAPK10 (JNK3), 12.5 ng inactive MAPKAPK2, and 2  $\mu$ M Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### MAPK14 (p38 alpha)

The 2X MAPK14 (p38 alpha) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10  $\mu$ L Kinase Reaction consists of 0.006 - 0.02 ng MAPK14 (p38 alpha), 6.5 ng inactive MAPKAPK2, and 2  $\mu$ M Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5  $\mu$ L of a 1:1024 dilution of Development Reagent A is added.

#### MAPK8 (JNK1)

The 2X MAPK8 (JNK1) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 2.5 - 10 ng MAPK8 (JNK1), 25 ng inactive MAPKAPK2, and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 34 of 40

#### MAPK9 (JNK2)

The 2X MAPK9 (JNK2) / inactive MAPKAPK2 / Ser/Thr 04 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 2 mM DTT. The final 10 μL Kinase Reaction consists of 0.25 - 1 ng MAPK9 (JNK2), 12.5 ng inactive MAPKAPK2, and 2 μM Ser/Thr 04 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA, 1 mM DTT. After the 1 hour Kinase Reaction incubation, 5 μL of a 1:1024 dilution of Development Reagent A is added.

#### PDK<sub>1</sub>

The 2X PDK1 / inactive AKT2 (PKB beta) / Ser/Thr 06 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 5 - 20 ng PDK1, 150 ng inactive AKT2 (PKB beta), and 2 µM Ser/Thr 06 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:4096 dilution of Development Reagent A is added.

#### RAF1 (cRAF) Y340D Y341D

The 2X RAF1 (cRAF) Y340D Y341D / inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2) / Ser/Thr 03 mixture is prepared in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. The final 10 µL Kinase Reaction consists of 0.006 - 0.02 ng RAF1 (cRAF) Y340D Y341D, 1X inactive MAP2K1 (MEK1) / inactive MAPK1 (ERK2), and 2 µM Ser/Thr 03 in 50 mM HEPES pH 7.5, 0.01% BRIJ-35, 10 mM MgCl2, 1 mM EGTA. After the 1 hour Kinase Reaction incubation, 5 µL of a 1:1024 dilution of Development Reagent A is added.



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 35 of 40

## Table of Kinase ATP Km Bins and Inhibitor Validation

The table below provides specifications and data around each kinase. The representative IC50 value with a known inhibitor for each kinase was determined at the ATP bin nearest to the ATP Km app, unless indicated with an asterisk (\*) in which case the IC50 value was determined at 100  $\mu$ M ATP.

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
ABL1	Tyr 02	12	10	Tyrphostin AG1478	326
ABL1 E255K	Tyr 02	4.2	5	Staurosporine	71.1
ABL1 F317I	Tyr 02	15	10	Staurosporine	205
ABL1 F317L	Tyr 02	14	10	Staurosporine	214
ABL1 G250E	Tyr 02	5.4	5	Staurosporine	29.9
ABL1 T315I	Tyr 02	2.8	5	Staurosporine	12.3
ABL1 Y253F	Tyr 02	11.8	10	Staurosporine	44.1
ABL2 (Arg)	Tyr 02	30	25	Tyrphostin AG1478	731
ACVR1B (ALK4)	Ser/Thr 16	1.6	5	SB 431542	972
ADRBK1 (GRK2)	Ser/Thr 16	13.3	10	Staurosporine	1360
ADRBK2 (GRK3)	Ser/Thr 16	11.7	10	Staurosporine	1670
AKT1 (PKB alpha)	Ser/Thr 06	75	75	Staurosporine	8.85
AKT2 (PKB beta)	Ser/Thr 06	200	200	Staurosporine	47.8
AKT3 (PKB gamma)	Ser/Thr 06	100	100	Staurosporine	9.49
ALK	Tyr 01	30	25	Staurosporine	10.6
AMPK (A1/B2/G2)	Ser/Thr 25	9	10	Staurosporine	0.448
AMPK (A1/B2/G3)	Ser/Thr 25	13	10	Staurosporine	0.654
AMPK (A2/B1/G2)	Ser/Thr 25	11	10	Staurosporine	0.395
AMPK (A2/B1/G3)	Ser/Thr 25	24	25	Staurosporine	0.809
AMPK (A2/B2/G3)	Ser/Thr 25	40	50	Staurosporine	0.319
AMPK A1/B1/G1	Ser/Thr 23	43	50	Staurosporine	0.203
AMPK A2/B1/G1	Ser/Thr 23	148	150	Staurosporine	0.799
AURKA (Aurora A)	Ser/Thr 01	10	10	Staurosporine	2.84
AURKB (Aurora B)	Ser/Thr 01	81	75	Staurosporine	5.04
AURKC (Aurora C)	Ser/Thr 19	26	25	Staurosporine	4.33
AXL	Tyr 06	71	75	Staurosporine	3.77
BLK	Tyr 01	30	25	Tyrphostin AG1478	738
BMX	Tyr 01	107	100	Staurosporine	756 15.4
BRAF	Ser/Thr 03	Cascade	100	Staurosporine	17.3 *
BRAF V599E	Ser/Thr 03	Cascade	100	•	24.0 *
	Ser/Thr 21	32	25	Staurosporine	24.0
BRSK1 (SAD1)		32 36		Staurosporine	
BTK	Tyr 01		25	Tyrphostin AG1478	1800
CAMK1D (CaMKI delta)	Ser/Thr 25	28	25	Staurosporine	19.7
CAMK1G (CAMKI gamma)	Ser/Thr 23	294	300	Staurosporine	13.9
CAMK2A (CaMKII alpha)	Ser/Thr 04	10	10	Staurosporine	0.556
CAMK2B (CaMKII beta)	Ser/Thr 17	76	75	Staurosporine	0.520
CAMK2D (CaMKII delta)	Ser/Thr 04	6	5	Staurosporine	0.287
CAMK4 (CaMKIV)	Ser/Thr 13	18	25	Staurosporine	50.7
CDC42 BPA (MRCKA)	Ser/Thr 13	1	5	Staurosporine	10.9
CDC42 BPB (MRCKB)	Ser/Thr 13	1	5	Staurosporine	15.2
CDC42 BPG (MRCKG)	Ser/Thr 13	2	5	Staurosporine	3.80
CDK1/cyclin B	Ser/Thr 18	34	25	Staurosporine	4.10
CDK17/cyclin Y	Ser/Thr 12	47	50	Staurosporine	20.2
CDK18/cyclin Y	Ser/Thr 12	74	75	Staurosporine	40.7
CDK2/cyclin A	Ser/Thr 12	31	25	Staurosporine	2.16



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 36 of 40

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
CDK5/p25	Ser/Thr 12	17	10	Staurosporine	4.03
CDK5/p35	Ser/Thr 12	8	10	Staurosporine	4.31
CDKL5	Ser/Thr 18	516	500	Staurosporine	401
CHEK1 (CHK1)	Ser/Thr 19	53	50	Staurosporine	3.14
CHEK2 (CHK2)	Ser/Thr 07	84	75	Staurosporine	15.9
CLK1	Ser/Thr 09	24	25	Staurosporine	101
CLK2	Ser/Thr 06	30	25	Staurosporine	8.22
CLK3	Ser/Thr 18	128	150	Staurosporine	1160
CSF1R (FMS)	Tyr 01	450	500	Tyrphostin AG1478	3090
CSK	Tyr 02	15	10	Staurosporine	54.3
CSNK1A1 (CK1 alpha 1)	Ser/Thr 11	2	5	TBB ·	12600
CSNK1A1L	Ser/Thr 11	2	5	TBB	14500
CSNK1D (CK1 delta)	Ser/Thr 11	4	5	TBB	2420
CSNK1E (CK1 epsilon)	Ser/Thr 11	2	5	TBB	3070
CSNK1E (CK1 epsilon) R178C	Ser/Thr 11	20	25	TBB	2560
CSNK1G1 (CK1 gamma 1)	Ser/Thr 05	2	5	Chetomin	43.4
CSNK1G2 (CK1 gamma 2)	Ser/Thr 05	5	5	TBB	23400
CSNK1G3 (CK1 gamma 3)	Ser/Thr 05	4.4	5	TBB	54400
CSNK2A1 (CK2 alpha 1)	Ser/Thr 11	4	5	TBB	2870
CSNK2A2 (CK2 alpha 2)	Ser/Thr 11	46	50	TBB	2170
DAPK3 (ZIPK)	Ser/Thr 13	2.5	5	Staurosporine	16.6
DCAMKL1 (DCLK1)	Ser/Thr 23	261	300	Staurosporine	210
DCAMKL2 (DCK2)	Ser/Thr 17	149.5	150	Staurosporine	38.9
DNA-PK	Ser/Thr 26	17	25	PI-103	7.21
DYRK1A	Ser/Thr 18	99.7	100	Staurosporine	25.6
DYRK1B	Ser/Thr 18	86	75	Staurosporine	5.90
DYRK3	Ser/Thr 09	4.7	5	Staurosporine	83.1
DYRK4	Ser/Thr 09	2.2	5	TBB	6190
EEF2K	Ser/Thr 24	15	10	NH125	8080
EGFR (ErbB1)	Tyr 04	11.5	10	Staurosporine	51.5
EGFR (ErbB1) C797S	Tyr 04	2	5	Staurosporine	626
EGFR (ErbB1) G719C	Tyr 04	142	150	Staurosporine	6400
EGFR (ErbB1) G719S	Tvr 04	94	100	Staurosporine	3570
EGFR (ErbB1) L858R	Tyr 04	44.2	50	Staurosporine	71.6
EGFR (ErbB1) L861Q	Tyr 04	12.7	10	Staurosporine	60.2
EGFR (ErbB1) T790M	Tyr 04	10	10	Staurosporine	0.601
EGFR (ErbB1) T790M C797S L858R	Tyr 04	6	5	Staurosporine	1.12
EGFR (ErbB1) T790M L858R	Tyr 04	26	25	Staurosporine	0.360
EPHA1	Tyr 02	18.5	25	Staurosporine	60.0
EPHA2	Tyr 01	65.4	75	Staurosporine	202
EPHA4	Tyr 02	106	100	Staurosporine	65.6
EPHA5	Tyr 01	129	150	Staurosporine	60.1
EPHA8	Tyr 02	123	100	Staurosporine	94.2
EPHB1	Tyr 02	61.4	50	Staurosporine	74.3
EPHB2	Tyr 02	66	75	Staurosporine	82.7
EPHB3	Tyr 02	70	75	PP2	516
EPHB4	Tyr 01	115	100	Tyrphostin AG1478	954
ERBB2 (HER2)	Tyr 06	14.1	10	Tyrphostin AG1478	122
ERBB4 (HER4)	Tyr 01	5	5	Tyrphostin AG1478	127
FER	Tyr 05	18.5	25	Staurosporine	2.21
FES (FPS)	Tyr 01	30	25	Staurosporine	2.22
FGFR1	Tyr 04	20	25	Staurosporine	6.92
FGFR2	Tyr 04	1	5	Staurosporine	2.80
FGFR2 N549H	Tyr 04	1	5	Staurosporine	19.9
	<i>j.</i>	•	-	1	



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 37 of 40

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (μM)	Inhibitor	IC50 (nM)
FGFR3	Tyr 04	80	75	Staurosporine	41.4
FGFR3 K650E	Tyr 04	6	5	Staurosporine	7.69
FGFR3 V555M	Tyr 04	2	5	Staurosporine	1.28
FGFR4	Tyr 04	162	150	Staurosporine	147
FGR	Tyr 02	10	10	Tyrphostin AG1478	602
FLT1 (VEGFR1)	Tyr 04	158	150	Staurosporine	24.4
FLT3	Tyr 02	470	500	Tyrphostin AG1478	1910
FLT3 D835Y	Tyr 02	18.8	25	Staurosporine	0.254
FLT4 (VEGFR3)	Tyr 04	3.8	5	Staurosporine	7.58
FRAP1 (mTOR)	Ser/Thr 11	11	10	PI-103	33.0
FRK (PTK5)	Tyr 01	51.7	50	Staurosporine	9.39
FYN CDK4	Tyr 02	85 12	75 10	Tyrphostin AG1478	5300
GRK4 GRK5	Ser/Thr 16 Ser/Thr 16	12 3	10 5	Staurosporine	125 144
GRK6	Ser/Thr 16	3 11.7	10	Staurosporine	59.0
GRK7	Ser/Thr 16	10.5	10	Staurosporine	3.50
GSK3A (GSK3 alpha)	Ser/Thr 09	9	10	Staurosporine Staurosporine	13.7
GSK3B (GSK3 beta)	Ser/Thr 09	7	10	Staurosporine	10.8
HCK	Tyr 02	, 24	25	Tyrphostin AG1478	656
HIPK1 (Myak)	Ser/Thr 09	5	5	TBB	1570
HIPK2	Ser/Thr 09	17	10	Staurosporine	534
HIPK3 (YAK1)	Ser/Thr 18	22	25	TBB	3030
HIPK4	Ser/Thr 18	39	50	Staurosporine	693
IGF1R	Tyr 01	140	150	Staurosporine	124
IKBKB (IKK beta)	Ser/Thr 05	5	5	Staurosporine	340
IKBKE (IKK epsilon)	Ser/Thr 11	16	10	Staurosporine	5.12
INSR	Tyr 01	20	25	Staurosporine	69.9
INSRR (IRR)	Tyr 04	55	50	Staurosporine	110
IRAK4 ` ´	Ser/Thr 07	34	25	Staurosporine	19.8
ITK	Tyr 01	5.6	5	Staurosporine	16.2
JAK1	Tyr 06	87	75	Staurosporine	1.86
JAK2	Tyr 06	31	25	Staurosporine	0.456
JAK2 JH1 JH2	Tyr 06	46	50	Staurosporine	0.779
JAK2 JH1 JH2 V617F	Tyr 06	49	50	Staurosporine	0.701
JAK3	Tyr 06	14	10	Staurosporine	0.800
KDR (VEGFR2)	Tyr 01	78	75	Staurosporine	5.79
KIT	Tyr 06	284	300	Staurosporine	492
KIT T670I	Tyr 06	220	200	Staurosporine	133
KIT V559D	Tyr 06	6	5	Staurosporine	7.49
KIT V559D V654A	Tyr 06	2	5	Staurosporine	8.72
KIT V560G	Tyr 06	5	5	Staurosporine	8.25
KSR2	Ser/Thr 17	15	10	NH125	8410
LCK	Tyr 02	45	50	Tyrphostin AG1478	631
LTK (TYK1)	Tyr 06	82	75 25	Staurosporine	7.38
LYNA	Tyr 02	26 25	25 25	Tyrphostin AG1478	283 159
LYN B MAP2K1 (MEK1)	Tyr 02	Cascade	100	Tyrphostin AG1478	1.98 *
MAP2K1 (MEK1) MAP2K2 (MEK2)	Ser/Thr 03 Ser/Thr 03	Cascade	100	Staurosporine Staurosporine	3.10 *
MAP2K6 (MKK6)	Ser/Thr 03	Cascade	100	Staurosporine	3.54 *
MAP3K19 (YSK4)	Ser/Thr 07	5	5	Staurosporine	12.9
MAP3K8 (COT)	Ser/Thr 03	Cascade	100	Staurosporine	18.5 *
MAP3K9 (MLK1)	Ser/Thr 07	73	75	Staurosporine	3.01
MAP4K2 (GCK)	Ser/Thr 07	109	100	Staurosporine	0.898
MAP4K4 (HGK)	Ser/Thr 07	12.7	10	Staurosporine	1.44
· - /			• •	1=	



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 38 of 40

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
MAP4K5 (KHS1)	Ser/Thr 07	55	50	Staurosporine	0.840
MAPK1 (ÈRK2)	Ser/Thr 03	100	100	Staurosporine	1640
MAPK10 (JNK3)	Ser/Thr 04	Cascade	100	Staurosporine	1440 *
MAPK11 (p38 beta)	Ser/Thr 15	39	50	PP2	3010
MAPK12 (p38 gamma)	Ser/Thr 03	16	10	Staurosporine	121
MAPK13 (p38 delta)	Ser/Thr 03	13	10	Staurosporine	250
MAPK14 (p38 alpha)	Ser/Thr 04	Cascade	100	Staurosporine .	3620 *
MAPK14 (p38 alpha) Direct	Ser/Thr 15	497	500	PP2 '	5900
MAPK3 (ERK1)	Ser/Thr 03	45	50	Staurosporine	1840
MAPK7 (ERK5)	Ser/Thr 04	17	10	NH125	7170
MAPK8 (JNK1)	Ser/Thr 04	Cascade	100	Staurosporine	1410 *
MAPK9 (JNK2)	Ser/Thr 04	Cascade	100	Staurosporine	2650 *
MAPKAPK2	Ser/Thr 04	2.5	5	Staurosporine	489
MAPKAPK3	Ser/Thr 04	200	200	Staurosporine	61600
MAPKAPK5 (PRAK)	Ser/Thr 04	14	10	Staurosporine	587
MARK1 (MARK)	Ser/Thr 21	7	5	Staurosporine	25.6
MARK2	Ser/Thr 21	12	10	Staurosporine	27.6
MARK3	Ser/Thr 25	7	5	Staurosporine	0.598
MARK4	Ser/Thr 25	16	10	Staurosporine	0.712
MATK (HYL)	Tyr 01	350	300	Staurosporine	373
MELK	Ser/Thr 17	30	25	Staurosporine	1.66
MERTK (cMER)	Tyr 02	15	10	Staurosporine	16.8
MET (cMet)	Tyr 06	64	50	Staurosporine	99.1
MET (cMet) Y1235D	Tyr 06	31	25	Staurosporine	201
MET M1250T	Tyr 06	14.1	10	Staurosporine	126
MINK1	Ser/Thr 07	26.5	25	Staurosporine	1.78
MKNK1 (MNK1)	Ser/Thr 07	103	100	Staurosporine	174
MST1R (RON)	Tyr 06	10.7	100	Staurosporine	64.0
MST4	Ser/Thr 07	28	25	Staurosporine	4.10
MUSK	Tyr 04	49.5	50	Staurosporine	7.69
MYLK2 (skMLCK)	Ser/Thr 13	310	300	Staurosporine	102
NEK1	Ser/Thr 07	118.7	100	Staurosporine	89.3
NEK2	Ser/Thr 07	150	150	Staurosporine	4930
NEK4	Ser/Thr 17	56.2	50	Staurosporine	288
NEK6	Ser/Thr 22	108	100	Chetomin	125
NEK9	Ser/Thr 07	90	100	Staurosporine	1190
NIM1K	Ser/Thr 25	11	100	Staurosporine	352
NTRK1 (TRKA)	Tyr 01	425	400	Staurosporine	5.78
NTRK2 (TRKB)	Tyr 01	22	25	Staurosporine	0.792
NTRK3 (TRKC)	Tyr 01	54	50	Staurosporine	1.94
PAK1	Ser/Thr 19	48.5	50	Staurosporine	1.27
PAK2 (PAK65)	Ser/Thr 20	89	75	Staurosporine	5.56
PAK3	Ser/Thr 20	101	100	Staurosporine	4.80
PAK4	Ser/Thr 20	3	5	Staurosporine	5.32
PAK6	Ser/Thr 20	8	10	Staurosporine	4.54
PAK7 (KIAA1264)	Ser/Thr 20	4	5	Staurosporine	5.89
PASK	Ser/Thr 07	53.3	50	Staurosporine	65.7
PDGFRA (PDGFR alpha)	Tyr 04	9	10	Staurosporine	5.19
PDGFRA D842V	Tyr 04	5.3	5	Staurosporine	5.77
PDGFRA T674I	Tyr 04	93	100	Staurosporine	5.90
PDGFRA V561D	Tyr 04	48	50	Staurosporine	0.940
PDGFRB (PDGFR beta)	Tyr 04	100	100	Staurosporine	8.90
PDK1	Ser/Thr 06	Cascade	100	Staurosporine	10.5 *
PDK1 Direct	Ser/Thr 07	27	25	Staurosporine	7.59
1 D. C. Dillook	551, 1111 07	-1	20	Stadioopoilio	7.00



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 39 of 40

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
PEAK1	Tyr 01	56	50	Staurosporine	8.94
PHKG1	Ser/Thr 07	63.3	75	Staurosporine	0.548
PHKG2	Ser/Thr 07	10	10	Staurosporine	1.48
PIM1	Ser/Thr 07	407	400	TBB	1120
PIM2	Ser/Thr 07	3	5	Staurosporine	24.6
PIM3	Ser/Thr 07	818	1000	Staurosporine	5.37
PKN1 (PRK1)	Ser/Thr 07	40	50	Staurosporine	6.75
PLK1	Ser/Thr 16	12.8	10	Staurosporine	617
PLK2	Ser/Thr 16	29.6	25	Staurosporine	367
PLK3	Ser/Thr 16	47.8	50	TBB	1910
PRKACA (PKA)	Ser/Thr 01	4	5	Staurosporine	1.70
PRKCA (PKC alpha)	Ser/Thr 07	35	25	Staurosporine	1.13
PRKCB1 (PKC beta I)	Ser/Thr 07	36	25	Staurosporine	1.63
PRKCB2 (PKC beta IÍ)	Ser/Thr 07	27	25	Staurosporine	0.925
PRKCD (PKC delta)	Ser/Thr 07	24	25	Staurosporine	0.763
PRKCE (PKC epsilon)	Ser/Thr 07	8	10	Staurosporine	1.32
PRKCG (PKC gamma)	Ser/Thr 07	21	25	Staurosporine	1.00
PRKCH (PKC eta)	Ser/Thr 07	35	25	Staurosporine	2.55
PRKCI (PKC iota)	Ser/Thr 07	25	25	Staurosporine	162
PRKCN (PKD3)	Ser/Thr 17	26	25	Staurosporine	3.63
PRKCQ (PKC theta)	Ser/Thr 07	100	100	Staurosporine	2.07
PRKCZ (PKC zeta)	Ser/Thr 07	4	5	Staurosporine	521
PRKD1 (PKC mu)	Ser/Thr 17	15	10	Staurosporine	3.45
PRKD2 (PKD2)	Ser/Thr 17	27	25	Staurosporine	2.18
PRKG1 \	Ser/Thr 01	20	25	Staurosporine	3.65
PRKG2 (PKG2)	Ser/Thr 01	177	150	Staurosporine	0.604
PRKX	Ser/Thr 01	17	10	Staurosporine	1.49
PTK2 (FAK)	Tyr 07	45	50	Staurosporine	51.8
PTK2B (FAK2)	Tyr 01	5	5	Staurosporine	12.0
PTK6 (Brk)	Tyr 01	82	75	Staurosporine	856
RAF1 (cRÁF) Y340D Y341D	Ser/Thr 03	Cascade	100	Staurosporine	37.2 *
RET ´	Tyr 02	11	10	Staurosporine	2.89
RET A883F	Tyr 04	10	10	Staurosporine	11.6
RET S891A	Tyr 06	8	10	Staurosporine	0.721
RET V804E	Tyr 04	50	50	Staurosporine	2.29
RET V804L	Tyr 02	5	5	Staurosporine	2.06
RET Y791F	Tyr 02	12	10	Staurosporine	3.12
ROCK1	Ser/Thr 07	3.1	5	Staurosporine	3.77
ROCK2	Ser/Thr 13	39.5	50	Staurosporine	2.49
ROS1	Tyr 01	61.4	50	Staurosporine	2.22
RPS6KA1 (RSK1)	Ser/Thr 06	6.5	5	Staurosporine	0.725
RPS6KA2 (RSK3)	Ser/Thr 06	8	10	Staurosporine	0.741
RPS6KA3 (RSK2)	Ser/Thr 06	18	10	Staurosporine	0.316
RPS6KA4 (MSK2)	Ser/Thr 01	14.1	10	Staurosporine	4.13
RPS6KA5 (MSK1)	Ser/Thr 01	39	50	Staurosporine	1.91
RPS6KA6 (RSK4)	Ser/Thr 20	30	25	Staurosporine	0.318
RPS6KB1 (p70S6K)	Ser/Thr 07	17	10	Staurosporine	2.44
SBK1 "	Ser/Thr 25	3	5	Staurosporine	29.4
SGK (SGK1)	Ser/Thr 06	36	25	Staurosporine	9.95
SGK2 ´	Ser/Thr 06	50	50	Staurosporine	52.7
SGKL (SGK3)	Ser/Thr 06	12	10	Staurosporine	59.5
SNF1LK2	Ser/Thr 25	59	50	Staurosporine	0.521
SRC	Tyr 02	50	50	Tyrphostin AG1478	1650
SRC N1	Tyr 02	50	50	Tyrphostin AG1478	1050



## Z'-LYTE™ Screening Protocol and Assay Conditions

Revised 29-Jan-2021

Page 40 of 40

	Z'-LYTE	ATP	ATP		
Assay	Substrate	Km app (µM)	Bin (µM)	Inhibitor	IC50 (nM)
SRMS (Srm)	Tyr 01	126.9	150	Staurosporine	262
SRPK1	Ser/Thr 18	32	25	Staurosporine	461
SRPK2	Ser/Thr 07	17.6	25	Staurosporine	1310
STK22B (TSSK2)	Ser/Thr 04	3	5	Staurosporine	14.4
STK22D (TSSK1)	Ser/Thr 04	9	10	Staurosporine	0.519
STK23 (MSSK1)	Ser/Thr 18	69	75	Staurosporine	3520
STK24 (MST3)	Ser/Thr 07	56	50	Staurosporine	5.87
STK25 (YSK1)	Ser/Thr 07	83	75	Staurosporine	4.29
STK3 (MST2)	Ser/Thr 07	50	50	Staurosporine	6.71
STK4 (MST1)	Ser/Thr 07	48.9	50	Staurosporine	7.36
SYK	Tyr 02	24.8	25	Staurosporine	0.445
TAOK2 (TAO1)	Ser/Thr 07	322	300	Staurosporine	16.2
TBK1	Ser/Thr 05	35	25	Staurosporine	1.68
TEK (Tie2)	Tyr 05	16.7	10	Staurosporine	56.6
TEK (TIE2) Y897S	Tyr 06	207	300	Staurosporine	263
TNK1	Ser/Thr 13	237	200	Staurosporine	2.78
TXK	Tyr 06	96	100	Staurosporine	36.7
TYK2	Tyr 03	23	25	Staurosporine	1.12
TYRO3 (RSE)	Tyr 02	27.7	25	Staurosporine	5.63
YES1	Tyr 02	20.3	25	Tyrphostin AG1478	807
ZAP70	Tyr 07	2	5	Staurosporine	475